234
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Impact of Global Consensus Statement on compliance with hormonal therapy for surgical menopause

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 300-305 | Received 18 Jul 2021, Accepted 26 Aug 2021, Published online: 02 Nov 2021

References

  • InterLACE study team. Variations in reproductive events across life: a pooled analysis of data from 505 147 women across 10 countries. Hum Reprod. 2019;34(5):881–893.
  • Nathorst-Böös J, von Schoultz B, Carlström K. Elective ovarian removal and estrogen replacement therapy-effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol. 1993;14(4):283–293.
  • Nappi RE, Sinforiani E, Mauri M, et al. Memory functioning at menopause: impact of age in ovariectomized women. Gynecol Obstet Invest. 1999;47(1):29–36.
  • Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821–828.
  • Lokkegaard E, Jovanovic Z, Heitmann BL, et al. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas. 2006;53(2):226–233.
  • Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–1083.
  • Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16(1):15–23.
  • Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol. 2009;113(5):1027–1037.
  • Rocca WA, Shuster LT, Grossardt BR, et al. Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo clinic cohort study of oophorectomy and aging. Womens Health (Lond). 2009;5(1):39–48.
  • Shuster LT, Rhodes DJ, Gostout BS, et al. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010;65(2):161–166.
  • Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
  • de Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric. 2013;16(2):203–204.
  • Neves ECM, Birkhauser M, Samsioe G, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas. 2015;81(1):88–92.
  • Baber RJ, Panay N, Fenton A, et al. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150.
  • de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Maturitas. 2016;91:153–155.
  • Wattanakumtornkul S, Chichareon S, Geater A, et al. Compliance with hormone replacement therapy at songklanagarind hospital. J Obstet Gynaecol Res. 2003;29(6):380–387.
  • Manonai J, Theppisai U, Suchartwatnachai C, et al. Compliance with hormone replacement therapy in thai women. Maturitas. 2003;44(3):201–205.
  • Rattanachaiyanont M, Angsuwatthana S, Inthawiwat S, et al. Hormonal replacement therapy in surgical menopause with underlying endometriosis. J Med Assoc Thailand. 2003;86(8):702–707.
  • Techatraisak K, Angsuwathana S, Rattanachaiyanont M, et al. Compliance and health consequences of menopausal hormonal therapy after surgical menopause: a retrospective study in Thailand. J Obstet Gynaecol Res. 2021;47(1):208–215.
  • Mejia-Gomez J, Gronwald J, Senter L, et al. Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. Menopause. 2020;27(12):1396–1402.
  • Novetsky AP, Boyd LR, Curtin JP. Trends in bilateral oophorectomy at the time of hysterectomy for benign disease. Obstet Gynecol. 2011;118(6):1280–1286.
  • Evans EC, Matteson KA, Orejuela FJ, et al. Salpingo-oophorectomy at the time of benign hysterectomy: a systematic review. Obstet Gynecol. 2016;128(3):476–485.
  • Langenberg P, Kjerulff KH, Stolley PD. Hormone replacement and menopausal symptoms following hysterectomy. Am J Epidemiol. 1997;146(10):870–880.
  • Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol. 2012;120(3):595–603.
  • Manzoli L, Di Giovanni P, Del Duca L, et al. Use of hormone replacement therapy in Italian women aged 50–70 years. Maturitas. 2004;49(3):241–251.
  • Chubaty A, Shandro MT, Schuurmans N, et al. Practice patterns with hormone therapy after surgical menopause. Maturitas. 2011;69(1):69–73.
  • Huang WF, Tsai YW, Hsiao FY, et al. Changes of the prescription of hormone therapy in menopausal women: an observational study in Taiwan. BMC Public Health. 2007;7(1):56.
  • Read MD, Edey KA, Hapeshi J, et al. Compliance with estrogen hormone replacement therapy after oophorectomy: a prospective study. Menopause Int. 2010;16(2):60–64.
  • Goldman GA, Kaplan B, Leiserowitz DM, et al. Compliance with hormone replacement therapy in postmenopausal women. A comparative study. Clin Exp Obstet Gynecol. 1998;25(1-2):18–19.
  • Hee P. Compliance to estrogen treatment one to three years after hysterectomy and bilateral salpingooophorectomy. The cohort’s lifestyle, knowledge of ERT, benefits etc. Acta Obstet Gynecol Scand. 1999;78(6):534–539.
  • Leung TN, Haines CJ, Chung TK. Five-year compliance with hormone replacement therapy in postmenopausal Chinese women in Hong Kong. Maturitas. 2001;39(3):195–201.
  • Chu K, Song Y, Chatooah ND, et al. The use and discontinuation of hormone replacement therapy in women in South China. Climacteric. 2018;21(1):47–52.
  • Oddens BJ, Boulet MJ. Hormone replacement therapy among Danish women aged 45–65 years: prevalence, determinants, and compliance. Obstet Gynecol. 1997;90(2):269–277.
  • Gavin NI, Thorp JM, Ohsfeldt RL. Determinants of hormone replacement therapy duration among postmenopausal women with intact uteri. Menopause. 2001;8(5):377–383.
  • Ushiroyama T, Ikeda A, Sakuma K, et al. The effect of physicians’ advice and recommendations on the compliance with hormone replacement therapy in the treatment of postmenopausal symptoms in Japanese women–a prospective study. J Med. 2004;35(1–6):163–169.
  • Corrado F, D’Anna R, Caputo F, et al. Compliance with hormone replacement therapy in postmenopausal Sicilian women. Eur J Obstet Gynecol Reprod Biol. 2005;118(2):225–228.
  • Mohammed-Cherif S, Briancon S, Potier de Courcy G, et al. Factors determining the use of hormone replacement therapy in recent naturally postmenopausal women participating in the French SU.VI.MAX cohort. Eur J Epidemiol. 2000;16(5):477–482.
  • Vestergaard P, Hermann AP, Gram J, et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas. 1997;28(2):137–145.
  • Karakoc B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause. 1998;5(2):102–106.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.